➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Colorcon
Harvard Business School
McKinsey

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Pirfenidone - Generic Drug Details

➤ Subscribe for complete access

« Back to Dashboard

What are the generic sources for pirfenidone and what is the scope of freedom to operate?

Pirfenidone is the generic ingredient in one branded drug marketed by Genentech Inc and is included in two NDAs. There are twenty-one patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Pirfenidone has two hundred and sixty-four patent family members in forty-five countries.

There are twenty-three drug master file entries for pirfenidone. One supplier is listed for this compound. There are five tentative approvals for this compound.

Recent Clinical Trials for pirfenidone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
parkview cancer institutePhase 1/Phase 2
University of Kansas Medical CenterPhase 1/Phase 2
Blade TherapeuticsPhase 1

See all pirfenidone clinical trials

Generic filers with tentative approvals for PIRFENIDONE
Applicant Application No. Strength Dosage Form
⤷  Try it Free⤷  Try it Free267MGCAPSULE;ORAL
⤷  Try it Free⤷  Try it Free801MGTABLET;ORAL
⤷  Try it Free⤷  Try it Free267MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for pirfenidone
Drug ClassPyridone
Paragraph IV (Patent) Challenges for PIRFENIDONE
Tradename Dosage Ingredient NDA Submissiondate
ESBRIET TABLET;ORAL pirfenidone 208780 2018-10-15
ESBRIET CAPSULE;ORAL pirfenidone 022535 2018-10-15

US Patents and Regulatory Information for pirfenidone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-003 Jan 11, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-002 Jan 11, 2017 DISCN Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Colorcon
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.